The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Antitumoral actions of the anti-obesity drug orlistat (Xenical™) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696 · cited 1×
“Thus, while overweight and obesity are associated with an increased risk of cancer development and death from all cancers [18, 19], high levels of FAS correlate with aggressive behaviors and poor prognosis in many human malignancies, including breast cancer [8–16].”
BackgroundChou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms
Calle, E. E., & Kaaks, R. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1408 · Cited by 3,613 · cited 1×
“Thus, while overweight and obesity are associated with an increased risk of cancer development and death from all cancers [18, 19], high levels of FAS correlate with aggressive behaviors and poor prognosis in many human malignancies, including breast cancer [8–16].”
BackgroundNagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858 · cited 1×
“Therefore, this distinct mechanism of action should not be affected by the mechanisms of resistance described for trastuzumab-based anti-Her2/neu immunotherapy [70–73].”
BackgroundFatty acid synthesis: a potential selective target for antineoplastic therapy
Kuhajda, F. P., Jenner, K., Wood, F. D., Hennigar, R. A., Jacobs, L. B., Dick, J. D., & Pasternack, G. R. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.14.6379 · Cited by 705 · cited 1×
“Remarkably, the differential expression of FAS between cancer and normal cells may provide a useful drug target for the development of novel therapeutic anti-metabolites [41].”
BackgroundSignal transduction and oncogenesis by ErbB/HER receptors
Marmor, M. D., Skaria, K. B., & Yarden, Y. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.06.002 · Cited by 389 · cited 1×
“As a part of our efforts to assess the role of FAS signaling on the survival and proliferation of breast cancer cells, we recently identified a novel bi-directional molecular linkage between breast cancer-associated FAS activity and Her2/neu (erbB-2), a well-characterized oncogene that is overexpressed in about 30% of…”
BackgroundP27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells
Nahta, R., Takahashi, T., Ueno, N. T., Hung, M.-C., & Esteva, F. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3900 · Cited by 298 · cited 1×
“Therefore, this distinct mechanism of action should not be affected by the mechanisms of resistance described for trastuzumab-based anti-Her2/neu immunotherapy [70–73].”
BackgroundA fatty acid synthase blockade induces tumor cell-cycle arrest by down-regulating Skp2
Knowles, L. M., Axelrod, F., Browne, C. D., & Smith, J. W. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405061200 · Cited by 146
Cited by
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis
Menendez, J. A., & Lupu, R. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2222 · Cited by 2,941
Self-citationReprogramming of fatty acid metabolism in cancer
Koundouros, N., & Poulogiannis, G. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0650-z · Cited by 1,614
Casares, D., Escribá, P. V., & Rosselló, C. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092167 · Cited by 808
Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma
Du, D., Liu, C., Qin, M., Zhang, X., Xi, T., Yuan, S., Hao, H., & Xiong, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.09.019 · Cited by 643
Increased lipogenesis in cancer cells: new players, novel targets
Swinnen, J. V., Brusselmans, K., & Verhoeven, G. (2006) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/01.mco.0000232894.28674.30 · Cited by 610
Metadata
- Authors
- Menendez, J. A., Vellon, L., & Lupu, R.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2005-08
- Volume
- 16
- Issue
- 8
- Pages
- 1253-1267
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2166751186
- Cited by
- 179
- References
- 8
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.